Latest filing published 26 Feb 2026 for Sangamo Therapeutics, INC, €2,120.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sandy Macrae discloses dealings in Sangamo Therapeutics, Inc to SEC (Form 4). Between 24 January 2018 and 25 February 2026, the trades on record add up to 38 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 26 February 2026, the filings show a share grant worth €13k in Sangamo Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations